Search results for "Myeloid"

showing 10 items of 538 documents

Transfusion-associated graft-versus-host disease-report of two further cases with an immunohistochemical analysis

1994

Summary Transfusion-associated graft-vs.-host disease (tGVHD) is a severe disease usually affecting immunocompromised hosts with haematological neoplasia. Two patients with acute leukaemia are reported, who developed fatal tGVHD after blood transfusions. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leucocyte adhesion molecule 1 (ELAM-1) expression and the CD4/CD8 ratio were assessed in lesional skin. ICAM-1 was strongly expressed on epidermal keratinocytes and endothelial cells (EC) and correlated with HLA-DR staining. VCAM-1 was strongly expressed on EC in the superficial dermal vessels. ELAM-1 stained weakly on EC in some of the su…

Pathologymedicine.medical_specialtyBlood transfusionCD3medicine.medical_treatmentIntercellular Adhesion Molecule-1CD4-CD8 RatioGraft vs Host DiseaseVascular Cell Adhesion Molecule-1CD18DermatologyTransfusion-associated graft versus host diseaseFatal OutcomeHumansLeukemia-Lymphoma Adult T-CellMedicineSkinbiologybusiness.industryCell adhesion moleculeTransfusion ReactionMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseLeukemia Myeloid AcuteLeukemiaImmunologybiology.proteinFemalebusinessCell Adhesion MoleculesCD8Clinical and Experimental Dermatology
researchProduct

Granulocytic sarcoma of the oral cavity in a chronic myeloid leukemia patient : an unusual presentation

2009

Intraoral granulocytic sarcoma is an unusual manifestation of chronic or acute leukemia. The oral manifestations often involve enlargements of the gingival and mucosal tissue from direct leukemic cell infiltration. Only 38 cases have been reported in scientific literature to date. We present the case of a 47 year-old female who was diagnosed with chronic myeloid leukemia (CML) in December 2006. She was referred to a dentist for further evaluation, revealing generalized gingival overgrowth as well as periodontal, apical disease, and bleeding of the gums. An oral biopsy was performed and histological features revealed immature blast-like cells.

Pathologymedicine.medical_specialtyDiseaseMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesBiopsyMedicineHumansSarcoma MyeloidGeneral DentistryAcute leukemiamedicine.diagnostic_testbusiness.industryMyeloid leukemiaMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]LeukemiaOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleMouth NeoplasmsSarcomabusinessInfiltration (medical)
researchProduct

The bone marrow stroma in hematological neoplasms—a guilty bystander

2011

In the setting of hematological neoplasms, changes in the bone marrow (BM) stroma might arise from pressure exerted by the neoplastic clone in shaping a supportive microenvironment, or from chronic perturbation of the BM homeostasis. Under such conditions, alterations in the composition of the BM stroma can be profound, and could emerge as relevant prognostic factors. In this Review, we delineate the multifaceted contribution of the BM stroma to the pathobiology of several hematological neoplasms, and discuss the impact of stromal modifications on the natural course of these diseases. Specifically, we highlight the involvement of BM stromal components in lymphoid and myeloid malignancies, a…

Pathologymedicine.medical_specialtyMyeloidStromal cellbusiness.industrymedicine.diseaseArticleLymphomaBone marrow stroma hematological neoplasmsmedicine.anatomical_structureOncologyStromaBone MarrowHematologic NeoplasmsmedicineBystander effectAnimalsHumansHematological neoplasmBone marrowStromal CellsbusinessHomeostasisNature Reviews Clinical Oncology
researchProduct

Blastic Plasmacytoid Dendritic Cell Neoplasm

2020

Clinical and biological presentation of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) is depicted to highlight criteria that might alert physicians. Diagnosis of BPDCN is still challenging and requires (1) immunophenotyping of blood or bone marrow aspiration using several markers (CD4, CD56, HLA-DR, myeloid and lymphoid lineage markers) and should include pDC markers such as CD123, cTCL1, CD303, and CD304, and/or (2) pathologic analysis of cutaneous lesions, also with immunohistochemistry using markers specific to BPDCN.

Pathologymedicine.medical_specialtyMyeloidbusiness.industryLineage markersHematologyBlastic plasmacytoid dendritic cell neoplasm3. Good health03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureImmunophenotypingOncology030220 oncology & carcinogenesisMedicineImmunohistochemistryInterleukin-3 receptorBone marrowPresentation (obstetrics)business030215 immunologyHematology/Oncology Clinics of North America
researchProduct

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

2018

Abstract Alterations of the bone marrow (BM) immune-microenvironment characterize the progression of monoclonal gammopathies and the development of osteolytic bone disease in multiple myeloma (MM). MM patients exhibit immune dysfunctions as impaired dendritic, NK and T cells, whereas the onset of MM osteolytic lesions is associated to an increased prevalence of Th17 cells. Recently, the pathophysiological role of the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) pathway together with an increase of myeloid derived suppressor cells (MDSCs) in the induction of tumor tolerance and immune evasion has been underlined with a therapeutic relevance. However, unclear data on the express…

Pathologymedicine.medical_specialtyOsteolysisBone diseasebusiness.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryPeripheral blood mononuclear cellmedicine.anatomical_structuremedicineMyeloid-derived Suppressor CellBone marrowPrecordial catch syndromebusinessMonoclonal gammopathy of undetermined significanceMultiple myelomaBlood
researchProduct

The ins and outs of osteopontin.

2015

The continuous remodeling of progressing tumors demands non-physiologic production of extracellular matrix (ECM) proteins. Among them, osteopontin (OPN) has been largely involved in tumor progression and metastasis. We have recently discovered a new mechanism for OPN in the metastatic spread of mammary carcinoma providing local immunosuppression at the seeding site.

Pathologymedicine.medical_specialtybiologymedicine.medical_treatmentImmunologyImmunosuppressionMetastasimedicine.diseaseMetastasisMammary carcinomaExtracellular matrixOncologystomatognathic systemTumor progressionMyeloid-derived suppressor cellbiology.proteinCancer researchMyeloid-derived Suppressor CellmedicineImmunology and AllergyOsteopontinOsteopontinAuthor's ViewMetastasis; Myeloid-derived suppressor cells; Osteopontin; Immunology and Allergy; Oncology; ImmunologyOncoimmunology
researchProduct

Die Milzszintigraphie als Methode zur funktionellen Milzanalyse

1970

1. Percussion and palpation are only a superficial and subjective measure for the determination of a splenic tumor. Comparative scintigraphic and clinical investigations in more than 4,000 patients have shown that about 50% of spleens weighing between 600 and 750 g are not palpable. Considering the widespread use of radioisotope scanning it seems justified to claim that the size of the spleen during clinical investigation should be determined by a scan. In scientific problems one has to insist on the use of this method in any case. 2. Depending on the fact that until now no functional test for the spleen is available, it is of great importance that it is now possible to carry out a highly a…

Pathologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryMyeloid leukemiaSpleenMononuclear phagocyte systemBlood flowmedicine.diseasePalpationSplenic tumormedicine.anatomical_structuremedicineStage (cooking)Differential diagnosisbusiness
researchProduct

Trends in Incidence and Survival of Myeloid Malignancies Since 1980, in the Côte D'or Department, Burgundy, France.

2009

Abstract Abstract 3122 Poster Board III-59 Objective The Registry of Haematological Malignancies (HM) has been established on January 1st, 1980 in the department of Côte d'Or (pop 500 000 inhabitants). It was the first specialized registry in haematology in the world. During the course of 25 years (1980-2004), 5026 cases of HM were recorded including 1553 Myeloid malignancies (MM) in which entities not initially considered as malignant were taken in account such as Myelodysplastic syndrome (MDS) and some Myeloproliferative neoplasms (MPN). This allow us to present trends in incidence and survival of myeloid malignancies by entities since 1980. Method MM diagnosed in the population between …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyMyeloidHematologyRelative survivalbusiness.industryEssential thrombocythemiaIncidence (epidemiology)ImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistrymedicine.anatomical_structureInternal medicinemedicineChromosome abnormalitybusinesseducationSex ratioBlood
researchProduct

Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myelo…

2022

Despite progressive advances in understanding the molecular biology of acute myeloid leukemia (AML), the conventional therapeutic approach has not changed substantially, and the outcome for most patients is poor. Thus, continuous efforts on the discovery of new compounds with improved features are required. Following a multistep sequence, we have identified a new tetracyclic ring system with strong antiproliferative activity towards several haematological cell lines. The new compounds possess structural properties typical of inactive-state-binding kinase inhibitors and are structurally related to quizartinib which is known as type-II tyrosine kinase inhibitor. In particular, the high activi…

PharmacologyFMS-like tyrosine kinase 3 (FLT3)FLT3/ITD3][13]thiazolo[4Organic Chemistry2H-imidazo [2′1':23][13]thiazolo[45-e]isoindol-8-yl-phenylureas2H-imidazo [2′1':23][13]thiazolo[45-e]isoindol-8-yl-phenylureas; Acute myeloid leukemia (AML); FLT3/ITD; FMS-like tyrosine kinase 3 (FLT3); Internal tandem duplication (ITD)ApoptosisGeneral Medicine2H-imidazo [2′Leukemia Myeloid AcuteMiceInternal tandem duplication (ITD)fms-Like Tyrosine Kinase 35-e]isoindol-8-yl-phenylureasCell Line TumorDrug DiscoveryMutationAcute myeloid leukemia (AML)AnimalsHumansProtein Kinase Inhibitors1':2European journal of medicinal chemistry
researchProduct

Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.

2008

Although imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML), some patients develop resistance with progression of leukemia. Alternative or additional targeting of signaling pathways deregulated in bcr-abl-driven CML cells may provide a feasible option for improving clinical response and overcoming resistance. In this study, we show that carboxyamidotriazole (CAI), an orally bioavailable calcium influx and signal transduction inhibitor, is equally effective in inhibiting the proliferation and bcr-abl dependent- and independent-signaling pathways in imatinib-resistant CML cells. CAI inhibits phosphorylation of cellular proteins including STAT5 and CrkL a…

PhysiologyMAP Kinase Signaling SystemClinical BiochemistryFusion Proteins bcr-ablDown-RegulationApoptosisSignal transduction inhibitorPharmacologyPiperazineschemistry.chemical_compoundhemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansEnzyme InhibitorsPhosphotyrosineCMLneoplasmsIn Situ Hybridization FluorescenceChronic Myelogenous LeukemiaCell ProliferationCarboxyamidotriazolebusiness.industryCAIMyeloid leukemiaImatinibCell BiologyTriazolesmedicine.diseaseCRKLEnzyme ActivationGene Expression Regulation NeoplasticLeukemiaImatinib mesylatePyrimidineschemistryDrug Resistance NeoplasmMolecular ProbesBenzamidesimatinib resistanceImatinib Mesylateras ProteinsCML; imatinib resistance; CAICarboxyamidotriazolebusinesssignal transductionChronic myelogenous leukemiamedicine.drugJournal of cellular physiology
researchProduct